{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-012991","form_type":"8-K","ticker":"DRMA","cik":"0001853816","company_name":"Dermata Therapeutics, Inc.","filed_at":"2026-03-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.546576+00:00","generated_at":"2026-05-15T08:53:24.926209+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Dermata Therapeutics pivots to DTC skincare; reports year-end 2025 cash of $7.5M","bullets":["Strategic pivot from prescription derm to direct-to-consumer skincare brand Tome; first product launch mid-2026.","Cash and equivalents $7.5M at Dec 31, 2025 ($3.2M prior year); funded into Q1 2027.","Raised $15.4M gross in 2025/early 2026 including $4.125M private placement with insider participation.","R&D expenses fell to $2.9M from $8.2M as STAR-1 acne study completed; SG&A up to $4.8M on marketing.","Hired Kyra Peckaitis as VP Marketing; withdrew XYNGARI IND despite positive Phase 3 data."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-012991","json":"https://secwatch.observer/filing/0001493152-26-012991.json","markdown":"https://secwatch.observer/filing/0001493152-26-012991.md","text":"https://secwatch.observer/filing/0001493152-26-012991.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1853816/000149315226012991/0001493152-26-012991-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1853816/000149315226012991/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:53:24.926209+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"92456bcbdb16586efb3cd26a37c05722eae19378","claim":"Dermata Therapeutics, Inc. reported financial results for year ended December 31, 2025.","evidence_excerpt":"Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Year Ended 2025","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1853816/000149315226012991/0001493152-26-012991-index.htm","confidence":0.84,"family_label":"Earnings Releases","details":[{"label":"Period","value":"year ended December 31, 2025"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}